Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-155-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0017H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Cell culture lysate, Whole blood, PBMC

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.013 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 8.3%

Inter-assay (Run-to-Run)

n = 5,
CV = 9.9%

Spiking Recovery

99.1%

Dilutation Linearity

90.3%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-155-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Immune Response, Infection and Inflammation, Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

MicroRNA-155 is encoded by the MIR155 host gene (MIR155HG). MiR-155 is mainly expressed in the thymus and spleen; in the other tissues, its expression is negligible/undetectableunder normal physiological conditions. Target genes that are regulated by miR-155 include approximately 140 genes that encode for immunomodulatory proteins, tumor-suppressor proteins, and inflammatory-related proteins. Therefore, miR-155 is often associated with disorders, including cardiovascular diseases, inflammation, and cancer.

It is well-known that miR-155-5p is a proinflammatory, oncogenic miRNA, highly expressed in activated B and T cells as well as in macrophagesmiR-155-5p controls the function of lymphocytes and dendritic cells and is critical for normal immune function. In the gastrointestinal tract, abnormal miR-155 expression can be detected during Helicobacter pylori infection, and increased expression is observed in patients with inflammatory bowel disease (IBD) and colorectal cancer (CRC).

miR-155 can be detected in high levels in several solid tumors such as lung cancer, breast cancer, thyroid carcinoma, cervical cancer, and pancreatic cancer and it also serves as an indicator of poor prognosis for patients with these tumors. It promotes loss of genomic integrity in cancer cells by targeting genes involved in microsatellite instability and DNA repair, which strengthens the oncogenic features of miR-155 and highlights its role at the early steps of tumorigenesis.

Recently, numerous studies have demonstrated that miR-155 is associated also with hematological malignancies. Dysregulation of miR-155-5p expression has been linked to chronic lymphocytic leukemia (CLL) pathogenesis and miR-155-5p seems to be a promising, independent biomarker of unfavorable prognosis in CLL.

References to Summary

References to miR-155-5p

  • Xiaoyan W. et al. "MicroRNA-155: a Novel Armamentarium Against Inflammatory Diseases." Inflammation; 40 (2): 708–716 (2017).
  • Wan J. Xia L. Xu Wand Lu N. "Expression and Function of miR-155 in Diseases of the Gastrointestinal Tract." Int. J. Mol. Sci.; 17. 709 (2016).
  • Faraon I. Antonetti FR. Cardone J. Bonmassar E. "miR-155 gene: A typical multifunctional microRNA. Biochim. Biophys." Acta; 1792: 497–505 (2009).
  • Papageorgiou SG. Kontos CK. Diamantopoulos MA. Bouchla A. Glezou E. Bazani E. Pappa V. Scorilas A. "MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel. Independent Molecular Biomarker of Poor Prognosis." Disease Markers; (2017).
  • Rodriguez A. Vigorito E. Clare S. et al.. “Requirement of bic/microRNA-155 for normal immune function.” Science; 316 (5824): 608–611 (2007).
  • Volinia S. Calin GA. Liu CG. et al. "A microRNA expression signature of human solid tumors defines cancer gene targets". Proc. Natl. Acad. Sci.;103:2257–2261 (2006).
  • Iorio MV. Ferracin M. Liu CG. et al. "MicroRNA gene expression deregulation in human breast cancer". Cancer Res.; 65: 7065–7070 (2005).
  • Nikiforova MN. Tseng GC. Steward D. et al. "MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility". J.Clin. Endocrinol. Metab.; 93: 1600–1608 (2008).
  • Wang. X. Tang S. Le S-Y. et al. "Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth". PLoS ONE; (2008).
  • Szafranska AE. Davison TS. John J. et al. "MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma". Oncogene; 26: 4442–4452 (2007).
  • Pagotto S. Veronese A. Soranno A. et al. "Hsa-miR-155-5p drives aneuploidy at early stages of cellular transformation ". Oncotarget; 9 (16): 13036-13047 (2018).
  • Ranganath P. "MicroRNA-155 and its role in malignant hematopoiesis". Biomark. Insights; 10: 95–102 (2015).
Related Products Documents